We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are ...

We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are ...

The newly listed clinical-stage biotechnology company, Metsera Inc. rose 15.01% on Monday as the broader markets declined.

Metsera’s (NASDAQ:MTSR – Get Free Report) quiet period is set to expire on Wednesday, March 12th. Metsera had issued 15,277,778 shares in its initial public offering on January 31st. The total size of ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...

In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other stocks with at least $20 million in insider spending recently. As the stock market navigates ...

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s ...

Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 ...

In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other stocks with at least $10 million in insider spending recently. Since Donald Trump took office ...

BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...